Background

Anal squamous cell carcinoma (ASCC or anal SCC) is a rare, HPV-associated malignancy accounting for 2% of lower digestive system cancers. Usually these malignancies are detected early and successfully managed with chemoradiation. Uncommonly, these cancers recur or present with metastases. In this setting, cisplatin and 5-fluorouracil represents the only endorsed regimen. Beyond standard therapy, few therapeutic options exist. The purpose of this study is to identify other novel, potential targets and therapeutic options for this disease, utilizing a multiplatform approach.